The acquisition by OPKO is expected to be mutually beneficial. The huge appreciation in OPKO share price over the last few months has surely increased the value of the deal for PROLOR shareholders. OPKO is up 90% over the last one year, and has done well even over the longer term. It has appreciated by 380% over the last 5 years. The exact benefits of the merger will be known only over time, but it is expected to broaden OPKO's portfolio of therapies in selected specialty markets. PROLOR's product pipeline strengthens OPKO's pipeline. PROLOR's technology platforms and R&D infrastructure are expected support OPKO's growth strategy. A recent article on SA has recommended to buy OPKO mainly based on future prospects related to its innovation pipeline and backing of Dr. Phillip Frost. However, the author also mentioned that the stock is trading at very high valuations. Though the revenues have grown exponentially over the years, the company has a huge accumulated deficit. The level of debt is also high. As per the author, OPKO's 4KScore diagnostic test is one of the main hopes of the company with annual revenues estimated at $1.8 billion in due course. Dr. Frost's investment and active involvement in the company is reassuring considering his track record. OPKO has an agreement with Biozone (BZNE), another company where he has a stake, to explore the possibilities related to Biozone's proprietary drug delivery technology (QuSomes). The delivery technology can help in reducing cost of manufacture of formulations. QuSomes are likely to be in great demand from pharmaceuticals companies who are looking for more cost effective methods of manufacturing drugs. So the potential is surely there, but the stock is already factoring a lot of future positives. After such a huge rise, it is good to remain a bit cautious.